AI Article Synopsis
- MAO-B inhibitors may be used to treat Parkinson's disease even before functional deficits appear.
- For younger patients (under 75) with functional deficits, treatment typically starts with a dopamine agonist or MAO-B inhibitor; otherwise, levodopa is recommended.
- If patients experience severe symptoms like on-off fluctuations or dyskinesias despite treatment, surgical options and duodenal levodopa infusions can be explored, along with targeted rehabilitation.
Article Abstract
Following the diagnosis of Parkinson's disease, treatment may be initiated with MAO-B-inhibitor, even prior to the development of any functional deficit. For patients with a functional deficit who are younger (usually under 75 years of age) and otherwise in good condition, treatment should be started with a dopamine agonist or MAO-B-inhibitor. In other patients, initial treatment with levodopa is recommended. In the case of difficult on-off-symptoms and dyskinesias in spite of optimal treatment, surgical procedures and duodenal levodopa infusion should be considered. Rehabilitation should be targeted at specific problems associated with functional skills.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!